Page 4 - Genscript Biotech Corporation Stock Code News Today : Breaking News, Live Updates & Top Stories | Vimarsana
GenScript Biotech Reports First Half 2021 Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GenScript Announces Notice of Allowance for U S Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Kit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
GenScript to Host Gene & Cell Engineering Virtual Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
PISCATAWAY, N.J., April 28, 2021 /PRNewswire/ GenScript®, the world s leading reagents provider, announced today the launch of its Research Lentiviral Vector Packaging Service for cell line development, gene editing, and drug discovery. The service enables scientists to package their genetic material of choice using GenScript s proprietary platform to ensure consistent production of functional and intact viruses.
Lentiviruses in Cell Engineering
Access to high volume, high quality lentiviruses has become increasingly important in identifying therapeutics to fight COVID-19 and mutant strains of the virus as they emerge. Dr. Nevan Krogan, a molecular and systems biologist who leads The Krogan lab at the Quantitative Biosciences Institute (QBI) at UCSF and the Gladstone Institute of Data Science and Biosciences (GIDB), is using GenScript s lentiviruses to identify drugs against COVID-19.
Exclusive agreement for region brings GenScript s innovative cPass™ kit to Spain, Portugal and Andorra
LEIDEN, Netherlands & BILBAO, Spain (BUSINESS WIRE) GenScript Biotech (Netherlands) BV, a subsidiary of GenScript Biotech Corporation ( GenScript , Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra.
The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marked (Europe) and has received HSA provisional approval (Singapore), ANVISA in Brazil, ANMAT in Argentina and has recently re